1. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
- Author
-
Gressel GM, Frey MK, Norquist B, Senter L, Blank SV, and Urban RR
- Subjects
- Humans, Female, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Carcinoma, Ovarian Epithelial therapy, Carcinoma, Ovarian Epithelial drug therapy, Germ-Line Mutation, Genetic Testing, Poly(ADP-ribose) Polymerases genetics, Poly(ADP-ribose) Polymerases therapeutic use, Germ Cells pathology, BRCA1 Protein genetics, BRCA2 Protein genetics, Ovarian Neoplasms diagnosis, Ovarian Neoplasms genetics, Ovarian Neoplasms therapy, Antineoplastic Agents therapeutic use
- Abstract
Germline and somatic genetic testing have become critical components of care for people with ovarian cancer. The identification of germline and somatic pathogenic variants as well as homologous recombination deficiency can contribute to the prediction of treatment response, prognostic outcome, and suitability for targeted agents (e.g. poly (ADP-ribose) polymerase (PARP) inhibitors). Furthermore, identifying germline pathogenic variants can prompt cascade genetic testing for at-risk relatives. Despite the clinical benefits and consensus recommendations from several organizations calling for universal genetic testing in ovarian cancer, only about one third of patients complete germline or somatic genetic testing. The members of the Society of Gynecologic Oncology (SGO) Clinical Practice Committee have composed this statement to provide an overview of germline and somatic genetic testing for patients with epithelial ovarian cancer, focusing on available testing modalities and options for care delivery., Competing Interests: Declaration of Competing Interest Ms. Senter reports personal fees from AstraZeneca and GlaxoSmithKline, outside the submitted work. Dr. Urban reports personal fees from UpToDate, Inc., Access Hope, and Clinical Care Options, outside the submitted work. All other authors have nothing to disclose., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF